What percentage of individuals with a zero coronary calcium (CAC) score have atherosclerotic plaque detected on coronary CT angiography?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Atherosclerosis Detection in Patients with Zero CAC Score

Among symptomatic patients with a zero coronary artery calcium (CAC) score, approximately 13-17% have atherosclerotic plaque detected on coronary CT angiography (CCTA), with 3.5% having ≥50% stenosis and 1.4% having ≥70% stenosis. 1

Prevalence Data from Major Studies

The most robust evidence comes from the large, multicenter CONFIRM registry, which provides the highest-quality data for symptomatic populations:

  • In 10,037 symptomatic patients without known CAD who had CAC = 0, CCTA revealed:

    • Mild, nonobstructive CAD in 13% 1
    • Stenosis ≥50% in 3.5% 1
    • Stenosis ≥70% in 1.4% 1
  • Additional research studies in symptomatic populations show variable rates:

    • 8.9% prevalence of atherosclerotic plaque (with 32.3% of those having obstructive disease) 2
    • 9.3% frequency of atherosclerotic plaque (with 47% having significant coronary obstructions >50%) 3
    • 17.4% detection of noncalcified plaques (with 2.1% having significant stenosis) 4

Asymptomatic vs. Symptomatic Populations

The distinction between asymptomatic and symptomatic patients is critical for interpreting these numbers:

  • In asymptomatic individuals with CAC = 0, the prevalence is lower:

    • 7% had noncalcified plaque (6% non-obstructive, 1% obstructive) 5
    • The prognosis remains excellent with negligible future risk during median 22-month follow-up 5
  • In symptomatic patients, the false-negative rate is substantially higher:

    • Small single-center studies reported 0-39% of symptomatic patients with CAC = 0 had perfusion defects or high-grade stenosis 1
    • The CORE64 study found 19% of symptomatic patients with CAC = 0 had at least one vessel with ≥50% stenosis 6

Plaque Composition and Characteristics

The atherosclerotic burden in patients with zero CAC is predominantly noncalcified:

  • Among patients with CAC = 0 who have plaque, 97.9% of total plaque volume is noncalcified 7
  • These noncalcified plaques are completely missed by calcium scoring alone 7
  • The left anterior descending artery is the most frequently affected vessel (38.2% of plaques) 4
  • Proximal segments harbor 50% of plaques, mid-segments 42.7%, and distal segments 7.3% 4

Risk Factors Associated with Plaque Despite Zero CAC

Specific clinical characteristics increase the likelihood of finding atherosclerosis despite CAC = 0:

  • Age is independently associated with presence of noncalcified plaque 5
  • Male gender significantly increases risk 5
  • Diabetes mellitus is independently associated with plaque presence 5, 4
  • Hypertension is a significant risk factor in both genders 5, 4
  • Dyslipidemia independently predicts noncalcified plaque 5
  • Non-obese individuals paradoxically had higher frequency of plaques (90.6% vs 73.9%, OR 3.4) 3
  • Alcohol consumption was associated with higher plaque frequency (55.9% vs 34.8%, OR 3.4) 3

Age-Specific Considerations

Younger patients are disproportionately affected by the limitations of calcium scoring:

  • Documentation of obstructive CAD without CAC occurs more often in younger patients in whom atherosclerotic plaque has not advanced to the stage of calcification 1
  • In patients <40 years with obstructive CAD, 58% had CAC = 0, compared to only 9% among those aged 60-69 years 6

Clinical Implications and Pitfalls

Common pitfalls to avoid:

  • Never assume CAC = 0 excludes coronary disease in symptomatic patients – the false-negative rate is too high (3.5-19% depending on the study) 1, 6
  • Do not use CAC scoring as a surrogate for anatomical disease detection in symptomatic individuals – it was designed for risk stratification in asymptomatic populations 1
  • Recognize that calcium scoring has poor specificity for diagnosing obstructive CAD due to the modest relationship between calcification and luminal obstruction 8
  • In symptomatic patients with CAC = 0 and high clinical suspicion, proceed directly to CCTA or functional testing rather than relying on the calcium score to exclude disease 6

Prognostic Context

Despite the presence of plaque in some patients with CAC = 0, the overall prognosis remains excellent:

  • Annual mortality and MI risk remains below 1% for over 15 years in patients with CACS = 0 6
  • In asymptomatic patients with CAC = 0, only 0.47% experienced adverse cardiovascular events during 50-month follow-up 6
  • The excellent prognosis holds even in high-risk populations when CAC = 0 6

References

Related Questions

Can patients with known coronary artery disease (CAD) and stent placement take supplemental calcium?
Can a coronary calcium score greater than 0 be used to diagnose coronary artery disease (CAD) or atherosclerosis in an adult patient?
What is the recommended management for a patient with a high coronary calcium CT score, specifically a total calcium score of 212, total volume score of 160, and 82nd percentile, indicating a significant atherosclerotic plaque burden?
What is the significance and management of a coronary calcium score of 37 in the Left Anterior Descending (LAD) artery?
Is it reasonable to not initiate preventive measures with a Coronary Calcium CT score of 94.3 in the Left Anterior Descending (LAD) artery and a Stroke Volume Index (SVI) of 23.69 from a recent echocardiogram (echo) unless symptoms develop?
What is the recommended management for a cephalhaematoma in a newborn?
Can the MGS04 guideline be applied to the management of traumatic swelling?
Can sildenafil be used as first‑line oral therapy for adult WHO Group 1 pulmonary arterial hypertension, and what are the recommended dose, contraindications, monitoring, adverse effects, and alternative treatments?
What is the recommended use of pembrolizumab immunotherapy for PD‑L1 (programmed death‑ligand 1)‑positive triple‑negative breast cancer (TNBC) in metastatic and neoadjuvant settings, and are there approved indications for HER2‑positive or hormone‑receptor‑positive breast cancer?
How do whey protein concentrate, whey protein isolate, and whey protein hydrolysate differ, and which type is appropriate for a healthy adult, a lactose‑intolerant individual, a patient with chronic kidney disease, and an athlete seeking rapid post‑exercise recovery?
What is the recommended prednisone regimen, duration, contraindications, monitoring, and alternative treatments for extensive alopecia areata?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.